icon-    folder.gif   Conference Reports for NATAP  
 
  (APASL) 23rd Conference of the Asian Pacific
Association for the Study of the Liver
6-9 June
2013, Singapore
Back grey_arrow_rt.gif
 
 
 
All-Oral Therapy With Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment-Experienced Genotype 2/3 HCV-Infected Patients: Results of the Phase 3 FUSION Trial
 
 
  Reported by Jules Levin APASL 2013 June 6-10 Singapore
 
Stuart Gordon7, Jordan Feld1, David Nelson2, Kris V. Kowdley3, M. Tarek Al-Assi4, Ming Lin5, Hongmei Mo5, John McNally5, Diana M. Brainard5, William T. Symonds5, John G. McHutchison5, Keyur Patel6
 
7Henry Ford Health Systems, Detroit, MI, USA; 1University of Toronto, Ontario, Canada; 2University of Florida, Gainesville, FL, USA; 3Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, USA; 4Texas Digestive Disease Consultants, Arlington, TX, USA; 5Gilead Sciences, Inc., Foster City, CA, USA; 6Duke University, Durham, NC, USA
 
NEJM 4/2013: Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
http://www.natap.org/2013/EASL/EASL_08.htm

APASL1.gif

APASL2.gif

APASL3.gif

APASL4.gif

APASL5.gif

APASL6.gif

APASL7.gif